UA82828C2 - The use of enantiomeric pure escitalopram for treatment of depression - Google Patents

The use of enantiomeric pure escitalopram for treatment of depression

Info

Publication number
UA82828C2
UA82828C2 UA2003098415A UA2003098415A UA82828C2 UA 82828 C2 UA82828 C2 UA 82828C2 UA 2003098415 A UA2003098415 A UA 2003098415A UA 2003098415 A UA2003098415 A UA 2003098415A UA 82828 C2 UA82828 C2 UA 82828C2
Authority
UA
Ukraine
Prior art keywords
treatment
depression
disorders
disorder
enantiomeric pure
Prior art date
Application number
UA2003098415A
Other languages
English (en)
Inventor
Connie Sanchez
Arne Moerk
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of UA82828C2 publication Critical patent/UA82828C2/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Addiction (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
UA2003098415A 2001-05-01 2002-05-01 The use of enantiomeric pure escitalopram for treatment of depression UA82828C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DKPA200100684 2001-05-01
PCT/DK2002/000281 WO2002087566A1 (en) 2001-05-01 2002-05-01 The use of enantiomeric pure escitalopram

Publications (1)

Publication Number Publication Date
UA82828C2 true UA82828C2 (en) 2008-05-26

Family

ID=8160464

Family Applications (1)

Application Number Title Priority Date Filing Date
UA2003098415A UA82828C2 (en) 2001-05-01 2002-05-01 The use of enantiomeric pure escitalopram for treatment of depression

Country Status (25)

Country Link
US (7) US20040198809A1 (https=)
EP (1) EP1385503A1 (https=)
JP (1) JP2004527551A (https=)
KR (2) KR20100012089A (https=)
CN (1) CN1509169A (https=)
AR (1) AR033308A1 (https=)
AT (1) AT10974U1 (https=)
BG (1) BG108379A (https=)
BR (1) BR0208283A (https=)
CA (1) CA2445843A1 (https=)
CZ (1) CZ20033267A3 (https=)
EA (1) EA200301195A1 (https=)
HR (1) HRP20030744A2 (https=)
HU (1) HUP0400054A3 (https=)
IL (1) IL158031A0 (https=)
IS (1) IS6954A (https=)
ME (1) MEP5908A (https=)
MX (1) MXPA03008777A (https=)
NO (1) NO20034538D0 (https=)
PL (1) PL367480A1 (https=)
SK (1) SK14612003A3 (https=)
UA (1) UA82828C2 (https=)
WO (1) WO2002087566A1 (https=)
YU (1) YU85303A (https=)
ZA (1) ZA200307102B (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR021155A1 (es) * 1999-07-08 2002-06-12 Lundbeck & Co As H Tratamiento de desordenes neuroticos
WO2002087566A1 (en) * 2001-05-01 2002-11-07 H. Lundbeck A/S The use of enantiomeric pure escitalopram
AU2003287919B2 (en) * 2002-12-23 2009-11-12 H. Lundbeck A/S Escitalopram hydrobromide and a method for the preparation thereof
US20050037983A1 (en) * 2003-03-11 2005-02-17 Timothy Dinan Compositions and methods for the treatment of depression and other affective disorders
AR047553A1 (es) * 2003-07-04 2006-01-25 Lundbeck & Co As H La combinacion de un inhibidor de reabsorcion de serotonina y agomelatina
PL1691811T3 (pl) * 2003-12-11 2014-12-31 Sunovion Pharmaceuticals Inc Skojarzenie leku uspokajającego i modulatora neuroprzekaźnikowego oraz sposoby poprawy jakości snu i leczenia depresji
WO2005084643A1 (en) * 2004-03-05 2005-09-15 H. Lundbeck A/S Crystalline composition containing escitalopram oxalate
US20050196453A1 (en) 2004-03-05 2005-09-08 H. Lundbeck A/S Crystalline composition containing escitalopram
TWI347942B (en) * 2005-06-22 2011-09-01 Lundbeck & Co As H Crystalline base of escitalopram and orodispersible tablets comprising escitalopram base
EA200801081A1 (ru) 2005-10-14 2008-10-30 Х. Лундбекк А/С Способы лечения расстройств центральной нервной системы комбинацией малых доз эсциталопрама и бупропиона
JP2009511607A (ja) * 2005-10-14 2009-03-19 ハー・ルンドベック・アクチエゼルスカベット エスシタロプラムおよびブプロピオンを含有する安定な医薬製剤
US20070134322A1 (en) * 2005-12-14 2007-06-14 Forest Laboratories, Inc. Modified and pulsatile release pharmaceutical formulations of escitalopram
CN100353939C (zh) * 2006-01-05 2007-12-12 昆明积大制药有限公司 含西酞普兰和环糊精的抗抑郁口服药用组合物
US20070259952A1 (en) * 2006-05-02 2007-11-08 H. Lundbeck A/S Uses of escitalopram
TW200812993A (en) * 2006-05-02 2008-03-16 Lundbeck & Co As H New uses of escitalopram
CA2672925A1 (en) * 2006-10-20 2008-04-24 Ratiopharm Gmbh Escitalopram and solid pharmaceutical composition comprising the same
US20100003313A1 (en) * 2006-10-27 2010-01-07 Hisamitsu Pharmaceutical Co.,Inc. Adhesive skin patch
EP2017271A1 (en) 2007-07-06 2009-01-21 Aurobindo Pharma Limited Process for the preparation of escitalopram
US20090036468A1 (en) * 2007-08-03 2009-02-05 Forest Laboratories Holdings Limited Pharmaceutical compositions containing dopamine receptor ligands and methods of treatment using dopamine receptor ligands
SG185969A1 (en) * 2008-01-31 2012-12-28 Takeda Pharmaceutical Prophylactic or therapeutic agent for attention deficit/hyperactivity disorder
ITMI20080768A1 (it) * 2008-04-24 2009-10-25 Abiogen Pharma Spa Procedimento per la preparazione di un composto in forma cristallina di 3-benzil-2-metil-2,3,3a,4,5,6,7,7a-ottaidro-benzo[d]isossazol-4-one
JP5740300B2 (ja) * 2009-02-27 2015-06-24 久光製薬株式会社 経皮投与製剤
US20180071269A1 (en) 2015-08-12 2018-03-15 Tianxin Wang Therapeutical methods, formulations and nutraceutical formulations
US10702512B2 (en) * 2015-05-13 2020-07-07 A. Carlsson Research Ab Treatment of debilitating fatigue

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1143703A (https=) * 1965-03-18
US4079135A (en) * 1973-12-13 1978-03-14 Imperial Chemical Industries Limited Morpholine derivatives as antidepressants
GB1526331A (en) * 1976-01-14 1978-09-27 Kefalas As Phthalanes
GB8419963D0 (en) * 1984-08-06 1984-09-12 Lundbeck & Co As H Intermediate compound and method
GB8607313D0 (en) * 1986-03-25 1986-04-30 Ici Plc Pharmaceutical compositions
GB8814057D0 (en) * 1988-06-14 1988-07-20 Lundbeck & Co As H New enantiomers & their isolation
US4902710A (en) * 1988-12-14 1990-02-20 Eli Lilly And Company Serotonin and norepinephrine uptake inhibitors
US5114976A (en) * 1989-01-06 1992-05-19 Norden Michael J Method for treating certain psychiatric disorders and certain psychiatric symptoms
US4962128A (en) * 1989-11-02 1990-10-09 Pfizer Inc. Method of treating anxiety-related disorders using sertraline
US5296507A (en) * 1990-09-06 1994-03-22 H.Lundbeck A/S Treatment of cerbrovascular disorders
US5708035A (en) * 1991-02-04 1998-01-13 Sepracor Inc. Methods of use and compositions of R(-) fluoxetine
EP0714663A3 (en) * 1994-11-28 1997-01-15 Lilly Co Eli Potentiation of drug responses by serotonin 1A receptor antagonists
US5627196A (en) * 1995-01-17 1997-05-06 Eli Lilly And Company Compounds having effects on serotonin-related systems
US5554383A (en) * 1995-04-06 1996-09-10 Trustees Of Tufts College Veterinary method for clinically modifying the behavior of dogs exhibiting canine affective aggression
SE9501567D0 (sv) * 1995-04-27 1995-04-27 Astra Ab A new combination
US5846982A (en) * 1996-06-14 1998-12-08 Eli Lilly And Company Inhibition of serotonin reuptake
US5747494A (en) * 1996-06-28 1998-05-05 U C B S.A. Pharmaceutical compositions for the treatment of depressive disorders
US5958429A (en) * 1996-08-16 1999-09-28 Eli Lilly And Company Potentiation of serotonin response
ZA977967B (en) * 1996-09-23 1999-03-04 Lilly Co Eli Combination therapy for treatment of psychoses
US5776969A (en) * 1997-02-27 1998-07-07 Eli Lilly And Company Treatment of sleep disorders
US6069177A (en) * 1997-07-08 2000-05-30 The Hong Kong University Of Science And Technology 3-Hydroxy-propanamine derived neuronal reuptake inhibitors
SE9703375D0 (sv) * 1997-09-18 1997-09-18 Astra Ab A new combination
EA002770B1 (ru) * 1997-11-11 2002-08-29 Х.Лундбекк А/С Способ получения циталопрама
AU4850199A (en) * 1998-06-30 2000-01-17 Eli Lilly And Company Pyrrolidine and pyrroline derivatives having effects on serotonin related systems
US6150376A (en) * 1998-08-05 2000-11-21 Georgetown University Bi- and tri-cyclic aza compounds and their uses
PL199423B1 (pl) * 1998-10-20 2008-09-30 Lundbeck & Co As H Sposób wytwarzania citalopramu
DK1173431T4 (da) * 1999-04-14 2010-01-04 Lundbeck & Co As H Fremgangsmåde til fremstilling af citalopram
AR021155A1 (es) * 1999-07-08 2002-06-12 Lundbeck & Co As H Tratamiento de desordenes neuroticos
US6333357B1 (en) * 1999-11-05 2001-12-25 Be Able, Llc Behavior chemotherapy
UA77650C2 (en) * 1999-12-06 2007-01-15 Lundbeck & Co As H Use of serotonin reuptake inhibitor in combination with deramcyclane
GB2357762B (en) * 2000-03-13 2002-01-30 Lundbeck & Co As H Crystalline base of citalopram
US6469064B2 (en) * 2000-04-24 2002-10-22 Aryx Therapeutics Materials and methods for the treatment of depression
WO2002087566A1 (en) * 2001-05-01 2002-11-07 H. Lundbeck A/S The use of enantiomeric pure escitalopram

Also Published As

Publication number Publication date
NO20034538L (no) 2003-10-09
ZA200307102B (en) 2004-09-13
AT10974U1 (de) 2010-02-15
HUP0400054A2 (hu) 2004-04-28
BR0208283A (pt) 2004-03-09
AR033308A1 (es) 2003-12-10
US20040198811A1 (en) 2004-10-07
US20040192766A1 (en) 2004-09-30
US20040192765A1 (en) 2004-09-30
CA2445843A1 (en) 2002-11-07
US20080004338A1 (en) 2008-01-03
KR20040030609A (ko) 2004-04-09
EA200301195A1 (ru) 2004-04-29
IL158031A0 (en) 2004-03-28
WO2002087566A1 (en) 2002-11-07
HUP0400054A3 (en) 2007-03-28
CZ20033267A3 (en) 2004-06-16
BG108379A (bg) 2004-11-30
EP1385503A1 (en) 2004-02-04
US20040192764A1 (en) 2004-09-30
KR20100012089A (ko) 2010-02-05
MEP5908A (xx) 2010-02-10
PL367480A1 (en) 2005-02-21
IS6954A (is) 2003-09-15
US20040198809A1 (en) 2004-10-07
US20040198810A1 (en) 2004-10-07
YU85303A (sh) 2006-05-25
SK14612003A3 (sk) 2004-04-06
MXPA03008777A (es) 2004-02-12
JP2004527551A (ja) 2004-09-09
HRP20030744A2 (en) 2005-06-30
CN1509169A (zh) 2004-06-30
NO20034538D0 (no) 2003-10-09

Similar Documents

Publication Publication Date Title
UA82828C2 (en) The use of enantiomeric pure escitalopram for treatment of depression
NO20100333L (no) Behandling av nevrotiske forstyrrelser
WO2006054057A3 (en) New use for cannabinoid
PL367264A1 (en) Substituted sulfonamide compounds, process for their use as medicament for the treatment of cns disorders, obesity and type ii diabetes
MXPA03006771A (es) Anticuerpos modificados y metodos de uso.
MXPA03011515A (es) Nuevas composiciones de medicamentos sobre la base de agentes anticolinergicos, corticoesteroides y agentes betamimeticos.
DE69428791D1 (de) Verwendung vonModafinil zur Behandlung von Atemstillstand im Schlaf und zentral erregten Atembeschwerden
ATE450622T1 (de) Gene und proteine für verhinderung, vorhersage, prognose und therapie der herzgefäss-krankheit
DK1163224T3 (da) N-[2-hydroxy-3-(1-piperiinyl)propoxy]pyridin-1-oxid-3-carboximidoylchlorid og dets anvendelse i behandlingen af insulinresistens
MY141528A (en) Anilinopyrazole derivatives useful for the treatment of diabetes
EE05357B1 (et) Tablett, mis sisaldab v„hemalt kahte eristatavat segmenti, ning selle kasutamine
SE0102147D0 (sv) New methods
JP2006514952A5 (https=)
WO2003039468A3 (en) Antimnemonic therapy for hypermemory syndromes
MY136683A (en) Kappa opoid agonist for the treatment of irritable bladder
ATE408602T1 (de) Monohyroxycarbamezepin zur verwendung bei der herstellung eines medikaments zur behandlung von affektiver psychose, aufmerksamkeits störungen und neuropathischen schmerzen
MXPA04010816A (es) Acidos aminoalcanfosfonicos sustituidos para el tratamiento de dolor neuropatico, trastornos afectivos y de la atencion, esquizofrenia, tinitus, miopia y otros trastornos oculares.
WO2005056056A3 (en) The combination of a serotonin reuptake inhibitor and a histamine 3 receptor antagonist, inverse agonist or partial agonist
DE60034110D1 (de) Verwendung von 4-aminopyridin zur behandlung von peripheren neuropathien
NO20061167L (no) Kombinasjonen av en serotonin-reopptaksinhibitor og en glysintransporter type 1-inhibitor for behandling av depresjon
DE60215219D1 (de) Verwendung von darifenacin zur behandlung des harndrangs
ATE380884T1 (de) Verwendung von mirtazapin zur verbesserung der behandlung von menschen mit starken depressionen, welche träger des gens für apolipoprotein e4 sind.
WO2003027295A3 (en) Methods for diagnosis and treatment of diseases associated with altered expression of jak1
ATE286390T1 (de) Felabamat-derivate zur behandlung von neuropathischem schmerz
IL156639A0 (en) Phenethanolamine derivatives, methods for their preparation and pharmaceutical compositions containing them